By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Biotechnology have been published. According to news reporting originating in Tabriz, Iran, by NewsRx journalists, research stated, "Monoclonal antibody therapy has become a critical component of clinical treatment procedure for a variety of indications. Therapeutic antibodies have made the transition from conception to clinical reality over the past two decades."
The news reporters obtained a quote from the research from the Tabriz University of Medical Sciences, "Now, many of mAbs are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. In the future, the information drawn from genomemedical science and genome-informatics, that list the disease-related antigens useful for medical treatment, should be essential to develop the therapy using mAbs. Currently, the more attention is getting paid toward monoclonal antibody therapy. Several monoclonal antibodies, alone and in combination with other conventional therapies, are being tested in phase I and phase II clinical trials at the moment. Monoclonal antibody therapy can be done by using antibody fragments, antibody fusions with effector proteins and intrabodies. The large size and the long half-life of full-length antibody make them an inappropriate tool for radioimmunotherapy. Therefore, scientists produced some antibody fragments including scFv, Diabody and Nanobodies (sdAbs) which have smaller size besides maintaining the binding activity of the full-length molecule. Immunotoxin and Immunocytokines are consisting of toxin and cytokines fused to antibody fragments."
According to the news reporters, the research concluded: "An intrabody is produced by entering antibody into the cell and act against intracellular compartments."
For more information on this research see: Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Human Antibodies, 2013;22(1-2):9-13. Human Antibodies can be contacted at: IOS Press, Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands (see also technology.html">Biotechnology).
Our news correspondents report that additional information may be obtained by contacting L.A. Maleki, Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran Dept. of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran. Additional authors for this research include B. Baradaran, J. Majidi, M. Mohammadian and F.Z Shahneh.
The publisher of the journal Human Antibodies can be contacted at: IOS Press, Nieuwe Hemweg 6B, 1013 BG Amsterdam, The Netherlands.
Keywords for this news article include: Iran, Asia, Biotechnology, Tabriz, Treatment, Immunology, Immunotherapy, Blood Proteins, Immunoglobulins, Serum Globulins, Immunomodulation, Monoclonal Antibodies, Clinical Trials and Studies.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC